ATRIAL FLUTTER Clinical Trial
Official title:
The Usefulness of Intracardiac Echocardiography in Atrial Flutter Ablation - a Randomized Study
Background: Radiofrequency ablation of typical atrial flutter present the most effective
treament option in treatment of atrial flutter. Despite its high efficacy, due tovariant
anatomy of cavotricuspid isthmus (CTI), i.e. location of right coronary artery, pouches, the
achievment of complete bidirectional block across the CTI is sometimes chalenging.
Intracardiac echocardiography (ICE) is a very usefull tool for on-line vizualization of the
anatomy of the atria and also for the location of catheter position on CTI during ablation.
If the routine use of ICE is associated with easier atrial fluter ablation is not clear.
Methods: One hundred consecutive patients indicated for typical atrial flutter ablation will
be enrolled into the study. The patients will be randomized into group (A) ablation with use
of ICE and (B) ablation without ICE. The ablation will be done in both groups by two
diagnostic catheters (10-pole positioned in coronary sinus and 20-pole halo catheter
positioned in the right atrium) and radiofrequency ablation catheter. The end-point of the
ablation is the achievment of the bicidrectional block across the CTI. The end-points of the
study are 1) the total length of the procedure, 2) the fluoroscopy time and 3) the ablation
time. The safety end-point is clinically significant bleeding from the groin due to
additional puncture for ICE catheter.
Discussion: We hypothesize the use of ICE wil shorten the radiofrequency energy delivery,
fluoroscopy time and the length of the procedure without increasing the bleeding.
Introduction Radiofrequency ablation (RFA) of typical atrial flutteru is the most successful
method for treatment of atrial flutter. The acute (peri-procedural) efficacy is more than
95%. (1) Typical atrial flutter circuit uses the area between inferior caval vein and
tricuspid anulus, so a RFA of typical flutter is performed by providing a linear lesion from
inferior caval vein to tricuspid valve (this area is called as cavo-tricuspid isthmus). The
recurrence of atrial flutter after ablation, which are caused by non-transmural RF lesion,
are in less than 10% of cases. (2) During atrial flutter ablation, typically three
electrophysiological catheters are used. Two catheters are diagnostic (one 10-pole inserted
into coronary sinus and the other 20-pole inserted in the right atrium with the distal tip
laterally from the cavo-ticuspid isthmus). The third is ablation catheter, inserted in the CT
isthmus. The location of all three catheters is monitored by fluoroscopy and by the EP
signals on catheters. Also the ablation catheter during the ablation is monitored by
fluoroscopy and by the signals on the catheter.
Despite its high efficacy, the RFA of atrial flutter can be sometimes very difficult. The
most difficulties are done by anatomical differences in patients. (3, 4) In the area of CTI,
the rudimentary Eustachian valve can be present, which can hide the effective ablation of the
CI tissue. Moreover, deep pouches can be present in the TI area, which, if unrecognized, can
present the area of insufficient ablation. Both of them, Eustachian valve or pouches, are not
visible by fluoroscopy. In rare cases, a complete block in the CTI are is not achieved,
typically due to some anatomical difficulties. Furthermore, this anatomical obstacles can
lead to prolonged fluoroscopy time (to find the location of conduction in CTI rea), more RF
energy delivery and prolonged procedure time. Longer ablation time increases the risk of
ablation (such as right atrial perforation). Next possible anatomical obstacle is the right
coronary artery which can effective prevent sufficient ablation due to its cooling effect.
(5) Intracardiac echocardiography (ICE) is done by using intracardiac echo probe. The probe
is inserted in the right atrium, which allows the visualizing of the CTI area. (6, 7) ICE is
used for AF ablation in some centers, but its effect has never been validated in the
randomized study. The aim of our study is to assess whether routine use of ICE can lead to
decrease fluoroscopy time, decrease need for RFA delivery (i.e. number of ablations) and a
decrease procedure time. On the other hand, the safety endpoint will be to assess whether a
routine use of ICE is not associated with higher rate of complications. We hypothesize, the
use of ICE will shorten fluoroscopy, ablation and procedural time without increased number of
complication
Patients and methods:
Consecutive patients indicated due to standard criteria (i.e. according to the guidelines of
the European Society of Cardiology) for atrial flutter ablation will be enrolled. Exclusion
criterion will be the absence of written informed content and a history of recent femoral
vein thrombosis (< 6 months).
Randomization: 1 to 1 for ICE vs. non ICE RF ablation will be done routinely, as it is done
in the center. In the Ice group, ICE probe will be inserted through the left femoral vein in
the right atrium TH ICE will be used for the visualization of the anatomy of CTI area and the
visualization of the catheter during RF delivery. In case of the non-ICE group, RFA will be
done without ICE catheter, as it is done routinely now. In both groups, the diagnostic
catheters (10-pole CS and 20-po in the RA) and ablation catheter will be the same. In the
non-ICE group, the location of the catheters will be assessed by fluoroscopy and by signals
on catheters. At the end of ablation, total fluoroscopy time, the number and length of
ablation and the duration of procedure will be calculated. On the day and two weeks after the
procedure, the bleeding complication will be assessed.
End-points: the major end-points will be: 1) total procedure duration (min) 2) fluoroscopy
time 3) the number of ablations 4) the total duration of RF energy delivery. Major safety
end-point will be complication from left femoral ICE access.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Terminated |
NCT02317029 -
Comparison of Oxygen Interventions and Defibrillator Efficiency
|
N/A | |
Recruiting |
NCT01563848 -
Cryoablation in Patients With Atrial Flutter
|
Phase 2 | |
Completed |
NCT01229254 -
Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter
|
Phase 2 | |
Completed |
NCT00839657 -
Clarification of Optimal Anticoagulation Through Genetics
|
Phase 3 | |
Completed |
NCT02065388 -
Pharmacogenetic Dosing of Warfarin
|
Phase 3 | |
Completed |
NCT00232232 -
Use of Fish Oils to Prevent Atrial Mechanical Stunning and Atrial Remodeling Due to Atrial Arrhythmia
|
Phase 4 | |
Completed |
NCT04884100 -
enHEART - Exploring Full Content of Optical Signals to Enhance Cardiac Arrhythmia Screening
|
N/A | |
Completed |
NCT05468281 -
RAFF5 Proposal: Improve the Quality and Safety of Patients Seen in the Emergency Department for Acute Atrial Fibrillation and Flutter
|
||
Completed |
NCT03627143 -
Decreasing Hospital Admissions From the ED for AAFF
|
N/A | |
Completed |
NCT02917538 -
A Randomized Trial of Contact Force in Atrial Flutter Ablation
|
N/A | |
Enrolling by invitation |
NCT05903313 -
A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
|
||
Recruiting |
NCT05755074 -
Ablation of Typical Right Atrial Flutter
|
N/A | |
Recruiting |
NCT05883631 -
RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.
|
N/A | |
Recruiting |
NCT03272620 -
Atrial Fibrillation at the Viennese University Emergency Department
|
N/A | |
Completed |
NCT02810938 -
MIFI Flutter Registry - Ablation of Atrial Flutter With IntellaTip Sensor Technology
|
||
Recruiting |
NCT02591875 -
Atrial Flutter Ablation in a Real World Population
|
N/A | |
Completed |
NCT02268799 -
High Sensitivity Troponin T Levels Following DC Cardioversion for Atrial Fibrillation / Atrial Flutter
|
N/A | |
Completed |
NCT01914497 -
Dipole Density Mapping of Typical Atrial Flutter
|
N/A | |
Active, not recruiting |
NCT01976507 -
Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism
|
Phase 4 |